LABCORP HOLDINGS INC. (LH) Form 8-K — Oct 28, 2026
Labcorp reported strong Q3 2026 results with revenue of $3.81 billion, up 6.9% year-over-year, and adjusted EPS of $4.78, up 14.5% versus $4.18 in the prior-year quarter. The company raised its full-year 2026 guidance, moving enterprise revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70, up 18 cents at the midpoint. Labcorp advanced its M&A strategy with four announced or closed transactions, including agreements to acquire BioReference Health assets, Myriad Genetics' Prenatal Health business, and Millennium Health, all expected to be accretive to adjusted EPS in year one.
Key figures
- Eps
- 3.22
- Revenue
- 3810000000
- Guidance
- FY2026 enterprise revenue growth of 5.9%-6.7%; adjusted EPS $18.30-$18.70; free cash flow $1,240-$1,360 million
- Net Income
- 262800000
- Total Debt
- 5850000000
- Revenue Yoy
- 6.9%
- Cash Position
- 261800000
- Backlog
- 8920000000
- Adjusted eps q3
- 4.78
- Ttm book to bill
- 1.1
- Free cash flow q3
- 412200000
- Adjusted eps growth
- 14.5%
- Biopharma revenue q3
- 866700000
- Q3 acquisition spend
- 255500000
- Operating cash flow q3
- 563800000
- Adjusted operating margin
- 15.0%
- Share repurchase remaining
- 1400000000
- Adjusted operating income q3
- 570000000
- Quarterly dividend per share
- 0.72
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.